Medical University of South Carolina-ko ikertzaileekin lankidetzan egindako argitalpenak (50)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  3. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  4. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  5. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology

  6. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

  7. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

2023

  1. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation

    Molecular Metabolism, Vol. 78

  2. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

  3. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Cancer, Vol. 129, Núm. 12, pp. 1846-1855

2022

  1. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial

    Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2019

  1. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2018

  1. Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

2017

  1. Pictorial review of surgical anatomy in adult congenital heart disease

    Journal of Thoracic Imaging, Vol. 32, Núm. 4, pp. 217-232

2015

  1. State of the Art: Iterative CT reconstruction techniques1

    Radiology, Vol. 276, Núm. 2, pp. 339-357

2014

  1. Accuracy of dual-energy computed tomography for the measurement of iodine concentration using cardiac CT protocols: Validation in a phantom model

    European Radiology, Vol. 24, Núm. 2, pp. 512-518

2013

  1. CT angiography of coronary stents

    Imaging Coronary Arteries: Second Edition (Springer-Verlag Italia s.r.l.), pp. 115-130

2012

  1. CT of coronary heart disease: Part 1, CT of myocardial infarction, ischemia, and viability

    American Journal of Roentgenology, Vol. 198, Núm. 3, pp. 531-547